Fiasp

RSS

insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.

This EPAR was last updated on 23/09/2021

Authorisation details

Product details
Name
Fiasp
Agency product number
EMEA/H/C/004046
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB05
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
09/01/2017
Contact address
Novo Alle
2880 Bagsvaerd
Denmark

Product information

18/08/2021 Fiasp - EMEA/H/C/004046 - R/0028

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Insulins and analogues for injection, fast-acting

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating
4 ratings